Andersson LK - Search Results

1

A surface exposed O-linked galactose residue destabilises the structure of a folded helix-loop-helix dimer.

Vijayalekshmi S, George SK, Andersson LK, Kihlberg J, Baltzer L. Vijayalekshmi S, et al. Among authors: andersson lk. Org Biomol Chem. 2003 Jul 21;1(14):2455-60. doi: 10.1039/b302847j. Org Biomol Chem. 2003. PMID: 12956061

2

Designed, folded polypeptide scaffolds that combine key biosensing events of recognition and reporting.

Enander K, Dolphin GT, Andersson LK, Liedberg B, Lundström I, Baltzer L. Enander K, et al. Among authors: andersson lk. J Org Chem. 2002 May 3;67(9):3120-3. doi: 10.1021/jo010954n. J Org Chem. 2002. PMID: 11975577 No abstract available.

3

Control of lysine reactivity in four-helix bundle proteins by site-selective pKa depression: expanding the versatility of proteins by postsynthetic functionalization.

Andersson LK, Caspersson M, Baltzer L. Andersson LK, et al. Chemistry. 2002 Aug 16;8(16):3687-97. doi: 10.1002/1521-3765(20020816)8:16<3687::AID-CHEM3687>3.0.CO;2-8. Chemistry. 2002. PMID: 12203296

4

Multifunctional folded polypeptides from peptide synthesis and site-selective self-functionalization--practical scaffolds in aqueous solution.

Andersson LK, Dolphin GT, Baltzer L. Andersson LK, et al. Chembiochem. 2002 Aug 2;3(8):741-51. doi: 10.1002/1439-7633(20020802)3:8<741::AID-CBIC741>3.0.CO;2-O. Chembiochem. 2002. PMID: 12203972

5

Large-scale synthesis of peptides.

Andersson L, Blomberg L, Flegel M, Lepsa L, Nilsson B, Verlander M. Andersson L, et al. Biopolymers. 2000;55(3):227-50. doi: 10.1002/1097-0282(2000)55:3<227::AID-BIP50>3.0.CO;2-7. Biopolymers. 2000. PMID: 11074417 Review.

6

Determination of tolterodine and the 5-hydroxymethyl metabolite in plasma, serum and urine using gas chromatography-mass spectrometry.

Palmér L, Andersson L, Andersson T, Stenberg U. Palmér L, et al. J Pharm Biomed Anal. 1997 Sep;16(1):155-65. doi: 10.1016/s0731-7085(97)00023-x. J Pharm Biomed Anal. 1997. PMID: 9447563

7

Identification of Fmoc-beta-Ala-OH and Fmoc-beta-Ala-amino acid-OH as new impurities in Fmoc-protected amino acid derivatives.

Hlebowicz E, Andersen AJ, Andersson L, Moss BA. Hlebowicz E, et al. J Pept Res. 2005 Jan;65(1):90-7. doi: 10.1111/j.1399-3011.2004.00201.x. J Pept Res. 2005. PMID: 15686539

8

Protocolized reduction of non-resuscitation fluids versus usual care in septic shock patients (REDUSE): a randomized multicentre feasibility trial.

Lindén A, Spångfors M, Olsen MH, Fisher J, Lilja G, Sjövall F, Jungner M, Lengquist M, Kander T, Samuelsson L, Johansson J, Palmnäs E, Undén J, Oras J, Cronhjort M, Chew M, Linder A, Lipcsey M, Nielsen N, Jakobsen JC, Bentzer P; REDUSE Trial Group. Lindén A, et al. Crit Care. 2024 May 17;28(1):166. doi: 10.1186/s13054-024-04952-w. Crit Care. 2024. PMID: 38760833 Free PMC article. Clinical Trial.

9

Further urinary metabolites of delta 1-tetrahydrocannabinol in man.

Halldin MM, Andersson LK, Widman M, Hollister LE. Halldin MM, et al. Among authors: andersson lk. Arzneimittelforschung. 1982;32(9):1135-8. Arzneimittelforschung. 1982. PMID: 6293515

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9 results

Search Page